BOSTON, Oct. 29, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. ( Nasdaq: BBTX) (" Bambusa Therapeutics" or " Bambusa "), a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation, today announced the
Detailed findings from a randomized, double-blind, placebo-controlled cohort presented by Eric Simpson, M.D., M.C.R., of Oregon Health & Science University Presentation brings previously announced clinical findings together with pharmacokinetic and biomarker evidence for scientific discussion
Veteran life sciences executive brings more than 30 years of financial, strategic and business experience to support Bambusa’s continued growth and advancement of its pipeline BOSTON, Oct. 7, 2026 /PRNewswire/ — Bambusa Therapeutics, Inc. (“Bambusa Therapeutics” or “Bambusa”), a clinical-stage
First patient dosed as Bambusa expands global development of its long-acting bispecific antibody targeting both IL-4Rα and IL-31 High-concentration subcutaneous formulation designed to combine BBT001’s emerging profile of rapid, deep and durable clinical activity with convenient administration and
BBT001 delivered highly statistically significant and clinically meaningful improvement in EASI beginning at Week 1, with responses continuing to improve over time Fast-onset and potent itch relief was observed as early as Day 1 after the first dose alongside robust and durable suppression of Type
Dr. Liang brings deep biopharma finance, strategy, and capital markets expertise to support the company’s next phase of growth Bambusa also forms a Scientific Advisory Board of globally recognized leaders in biopharma, dermatology, and respiratory medicine to guide its immunology and inflammation
– BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 – – BBT002 demonstrated rapid, deep, and sustained biomarker effects through at least 8 weeks following multiple doses, consistent with the SAD data, with a
– BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 – – Preliminary Phase 1 data demonstrated rapid, deep, and sustained effects on key biomarkers for at least 8 weeks following a single dose, including pSTAT6
– Bambusa’s lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of atopic dermatitis (AD) and other type 2 inflammatory skin diseases – – Bambusa plans to announce topline
– Bambusa’s lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of atopic dermatitis (AD) and other type 2 inflammatory skin diseases – – BBT001 achieved rapid, deep, and
